Article
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Oct 2008
Khorashad Jamshid S, de Lavallade Hugues, Apperley Jane F, Milojkovic Dragana, Reid Alistair G, Bua Marco, Szydlo Richard, Olavarria Eduardo, Kaeda Jaspal, Goldman John M, Marin David
Abstract excerpt
PURPOSE: Kinase domain (KD) mutations in the BCR-ABL gene are associated with resistance to imatinib in chronic myeloid leukemia (CML) but their incidence and prognostic significance in chronic phase (CP) patients without resistance are unclear. PATIENTS AND METHODS: We analyzed outcome for 319 patients with CML-CP who were treated with imatinib; 171 were in early CP (ECP) and 148 were in late CP (LCP). Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.